BS Identity and Score for Myrbetriq (Astellas Pharma Inc.)

AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.

B
BS Level
Medical Devices, Pharma & Biotech
40.8 Avg BS

Based on 587 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: Myrbetriq (Astellas Pharma Inc.) (myrbetriq.com)

https://myrbetriq.com 📍 Industry: Medical Devices, Pharma & Biotech
35 BS / 100

This is a high-substance, low-technical-effort site where regulatory compliance prevents excessive BS, but stale data and zero structured data create a ‘ghost in the machine’ effect. The site relies on a 15-year-old study to drive its primary urgency claim, showing a reliance on legacy evidence. It is a functionally honest but technically neglected digital property.

Info Density Power-words vs. Substance ratio.
5
17% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
1
5% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
13
65% BS
Commodity Fingerprint Detection of industry clichés/templates.
4
27% BS
Identity & Authority Expert verifiability & Schema depth.
12
80% BS

Immediately implement MedicalWebPage and Organization schema to ground the brand’s digital authority. Update the epidemiological data to include post-2020 real-world evidence (RWE) to address the 15-year stale-date gap. Audit the heading hierarchy to remove the quadruple-repetition of the Symptom Summary markers. Replace generic trust theatre review counts with direct outbound citations to the peer-reviewed clinical studies referenced in Study 4.

Info Density Power-words vs. Substance ratio.
5 Impact Weight: 30 / 100
17% BS

The site exhibits high substance-to-fluff ratios due to regulatory requirements, featuring specific clinical study data such as the 52-week Myrbetriq Safety Study involving 812 people. Headings like [H2] What is Myrbetriq used for? and [H2] How Does Myrbetriq Work? are functional and direct, avoiding power-word saturation. However, information density is negatively impacted by extreme redundancy; the Doctor Conversation Guide headings and Symptom Summary blocks are repeated verbatim across multiple slots. Furthermore, the core epidemiological evidence cited (EpiLUTS 2011) is 15 years stale relative to the 2026 temporal anchor, reducing the weight of its ‘1 in 3’ claim.

When multiple URL variants exist, AI generates multiple embeddings of the same page. Run a Canonical Identity Stability Audit to see whether your site resolves into a single authoritative version.

Semantic Coherence Homepage promise vs. Sub-page reality.
1 Impact Weight: 20 / 100
5% BS

There is virtually zero semantic drift between the homepage signal and sub-page substance. The homepage H1 Doctor Conversation Guide leads directly to functional symptom assessment tools on sub-pages, and the mechanism-of-action promises are fulfilled by the detailed animated explanations on the What is Myrbetriq page. The messaging remains consistent, targeting patients with OAB symptoms and guiding them toward a healthcare professional (HCP) consultation. Some minor technical drift is noted in the heading hierarchy where the symptom quiz structure repeats unnecessarily, but the core clinical message is unwavering.

Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.

Trust & Proof Verifiable evidence vs. Trust Theatre.
13 Impact Weight: 20 / 100
65% BS

Trust theatre flags are high because the site displays a review_count of 3 on several pages while maintaining a proof_links_count of 0. While patient testimonials are common in pharma, presenting them without verified clinical outcome links or third-party validation constitutes trust theatre. Additionally, bold claims like ‘effective… within the first 4 to 8 weeks’ are substantiated only by internal references rather than direct outbound links to peer-reviewed publications.

Proof density is moderate; the site provides specific side-effect percentages (e.g., 9.2% for high blood pressure) and study parameters, which is high-quality evidence. However, the ratio is diluted by the lack of external verification paths (outbound links to ClinicalTrials.gov or PubMed). For every specific clinical data point, there are multiple repetitive blocks of legal text, which, while necessary, do not count as new evidentiary substance.

To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.

Commodity Fingerprint Detection of industry clichés/templates.
4 Impact Weight: 15 / 100
27% BS

The site follows a standard pharmaceutical ‘Product Site’ template, including the ubiquitous ISI scroll-box and resource library. Clichés like ‘Start the Conversation’ and ‘You Are Not Alone’ are industry-standard, though they serve a functional purpose in this context. The value proposition is technically unique, focused on the ‘different pathway’ (non-antimuscarinic) mechanism of action, which prevents the site from being a pure commodity copy-paste. Boilerplate sections like ‘OAB Resources’ are slightly generic but contain specific recipes and exercise tips that add marginal unique value.

Identity & Authority Expert verifiability & Schema depth.
12 Impact Weight: 15 / 100
80% BS

A significant authority gap exists due to the total absence of structured data (schema_json is null across all 4 pages). For a major medical product, the failure to implement Organization or MedicalWebPage schema suggests a technical credibility gap. While specific experts like Nurse Practitioner Diane Newman and Dr. David Stastkin are named in the OAB Resources, they lack Person schema or sameAs links to verify their digital footprint or professional credentials.

The marketing tone is subdued and clinical, which aligns well with the demonstrated data. The site avoids ‘breakthrough’ hyperbole, instead using grounded claims like ‘Myrbetriq was shown in studies to be effective.’ The disconnect is primarily temporal; the site presents data from 2011 as current situational evidence in 2026, creating a reality-gap in the reported prevalence of the condition.

Medical Devices, Pharma & Biotech BS: Myrbetriq (Astellas Pharma Inc.) (myrbetriq.com)

BS: 35/ 100

The site perfectly matches the Pharma & Biotech category, adhering to strict FDA-mandated disclosure patterns. Content is focused on a specific therapeutic area (OAB) and provides the required Important Safety Information (ISI) and Prescribing Information links.

The access layer decides whether your content even enters the model's world. Review the Crawlability & Indexation Framework to see how AI visible content differs from what humans see in the browser.

“The score of 35 is driven primarily by the complete lack of technical authority (Step 5) and the presence of trust theatre patterns (Step 3). Information density (Step 1) is relatively good due to pharma regulations, though penalized for extreme content repetition. This is a very low score for a marketing site but standard for a highly-regulated pharmaceutical landing page.”

Verified Analysis Date: May 31, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Get a Strategic Holistic View
FREE TOOLS
BUSINESS STRATEGY

Business Intelligence Engine

×
AI VISIBILITY